American Association for Cancer Research

Table 1

Main PK parameters of imatinib in CML patients on day 1 of treatment

Patient	Disease phase	Dose (mg)	T_max^a (h)	C_max (μg/ml)^b	AUC (μg/ml h)^c	t_1/2 (h)
001	BC	400	2	4.35	32.99	7.3
002	BC	400	1	3.29	27.80	15.2
0503	AP	400	3	1.08	13.20	14.2
0502	AP	400	2	2.89	34.00	11.4
0501	AP	400	1	1.53	18.00	12.8
001/udine	AP	400	1.5	3.18	40.40	12.7
00213	CP	400	2	1.33	15.10	13.1
00241	CP	400	2	1.17	15.80	13.5


		Mean		2.352	24.66	12.5
		95% CI		1.05	8.50	2.4


0504	AP	600	3	6.21	82.60	13.7
002/udine	AP	600	4	6.19	87.70	13.5
003	BC	600	1	4.80	44.90	10.6
004	BC	600	4	12.15	158.90	12.8
003/udine	AP	600	3	9.82	124.58	11.4


		Mean		7.83	99.74	12.5
		95% CI		3.80	54.15	1.4

Patient	Disease phase	Dose (mg)	T_max^a (h)	C_max (μg/ml)^b	AUC (μg/ml h)^c	t_1/2 (h)
001	BC	400	2	4.35	32.99	7.3
002	BC	400	1	3.29	27.80	15.2
0503	AP	400	3	1.08	13.20	14.2
0502	AP	400	2	2.89	34.00	11.4
0501	AP	400	1	1.53	18.00	12.8
001/udine	AP	400	1.5	3.18	40.40	12.7
00213	CP	400	2	1.33	15.10	13.1
00241	CP	400	2	1.17	15.80	13.5


		Mean		2.352	24.66	12.5
		95% CI		1.05	8.50	2.4


0504	AP	600	3	6.21	82.60	13.7
002/udine	AP	600	4	6.19	87.70	13.5
003	BC	600	1	4.80	44.90	10.6
004	BC	600	4	12.15	158.90	12.8
003/udine	AP	600	3	9.82	124.58	11.4


		Mean		7.83	99.74	12.5
		95% CI		3.80	54.15	1.4

T_max indicates the time (h) to peak concentrations.

C_max values were obtained from experimental data.

AUCs were calculated by trapezoidal rule.